Therapeutic efficacy of naked mAb compared with ADC
| Target . | Naked mAb . | ADC . |
|---|---|---|
| BCMA | No data available | Belantamab |
| Cytotoxic payload | Monomethylauristatin F (MMAF) | |
| Indication/status | R/R MM (FDA approved) | |
| Median PFS (mo) | 2.9 | |
| 1-y PFS | n.d. | |
| ORR, % | 31 | |
| Reference Clinical trial | 16 NCT03525678 | |
| CD19 | Tafasitamab | Loncastuximab |
| Cytotoxic payload | Pyrrolobenzodiazipine (PBD) | |
| Indication/status | R/R B-NHL (FDA approved) | R/R B-NHL (FDA approved) |
| Median PFS (mo) | 2.7 (DLBCL) 8.8 (FL) | 5.5 |
| 1-y PFS, % | 39 | n.d. |
| ORR, % | 29 | 59.4 (CR 24.1%) |
| Reference Clinical trial | 34 NCT01685008 | 35 NTC02669017 |
| CD20 | Rituximab | Ibritumomab |
| Cytotoxic payload | 90Y | |
| Indication/status | R/R B-NHL (FDA approved) | R/R B-NHL (FDA approved) |
| Median PFS (mo) | 10.1 | 11.2 |
| 1-y PFS | n.d. | n.d |
| ORR, % | 56 | 80 |
| Reference | 17 | 17 |
| CD22 | Epratuzumab | Inotuzumab |
| Cytotoxic payload | Calicheamicin | |
| Indication/status | R/R ALL (phase 2 study) | R/R ALL (FDA approved) |
| Median OS, mo | 3 | 7.7 |
| 1-y PFS | n.d. | n.d. |
| ORR, % | 50 | 80.7 CR |
| Reference Clinical trial | 36 NTC01219816 | 18 NCT01564784 |
| CD30 | SGN-30 | Brentuximab (FDA approved) |
| Cytotoxic payload | Monomethylauristatin E (MMAE) | |
| Indication/status | R/R HL (phase 2 study) | R/R HL |
| ORR, % | 0 (28.9% stable disease) | 86 |
| Median PFS | n.d. | n.d. |
| 2-y PFS | n.d. | 82.1% |
| Reference Clinical trial | 37 | 38 NCT01712490 |
| CD33 | Lintuzumab | Gemtuzumab |
| Cytotoxic payload | Calicheamicin | |
| Indication/status | R/R AML (phase 3 study, failed) | R/R AML (FDA approved) |
| ORR, % | 36 | 38.8 |
| Median PFS | Median survival 171.5 d | 1 y RFS 18.5% |
| Median OS | n.d. | 1 y OS 26% |
| Reference Clinical trial | 39 NCT00006045 | 40 |
| CD79b | No clinical data available | Polatuzumab |
| Cytotoxic payload | Monomethylauristatin E (MMAE) | |
| Indication/status | R/R DLBCL (FDA approved) | |
| Median PFS | 9.5 mo | |
| 1-y PFS | n.d. | |
| CR, % | 40 | |
| Reference Clinical trial | 24 NCT02257567 |
| Target . | Naked mAb . | ADC . |
|---|---|---|
| BCMA | No data available | Belantamab |
| Cytotoxic payload | Monomethylauristatin F (MMAF) | |
| Indication/status | R/R MM (FDA approved) | |
| Median PFS (mo) | 2.9 | |
| 1-y PFS | n.d. | |
| ORR, % | 31 | |
| Reference Clinical trial | 16 NCT03525678 | |
| CD19 | Tafasitamab | Loncastuximab |
| Cytotoxic payload | Pyrrolobenzodiazipine (PBD) | |
| Indication/status | R/R B-NHL (FDA approved) | R/R B-NHL (FDA approved) |
| Median PFS (mo) | 2.7 (DLBCL) 8.8 (FL) | 5.5 |
| 1-y PFS, % | 39 | n.d. |
| ORR, % | 29 | 59.4 (CR 24.1%) |
| Reference Clinical trial | 34 NCT01685008 | 35 NTC02669017 |
| CD20 | Rituximab | Ibritumomab |
| Cytotoxic payload | 90Y | |
| Indication/status | R/R B-NHL (FDA approved) | R/R B-NHL (FDA approved) |
| Median PFS (mo) | 10.1 | 11.2 |
| 1-y PFS | n.d. | n.d |
| ORR, % | 56 | 80 |
| Reference | 17 | 17 |
| CD22 | Epratuzumab | Inotuzumab |
| Cytotoxic payload | Calicheamicin | |
| Indication/status | R/R ALL (phase 2 study) | R/R ALL (FDA approved) |
| Median OS, mo | 3 | 7.7 |
| 1-y PFS | n.d. | n.d. |
| ORR, % | 50 | 80.7 CR |
| Reference Clinical trial | 36 NTC01219816 | 18 NCT01564784 |
| CD30 | SGN-30 | Brentuximab (FDA approved) |
| Cytotoxic payload | Monomethylauristatin E (MMAE) | |
| Indication/status | R/R HL (phase 2 study) | R/R HL |
| ORR, % | 0 (28.9% stable disease) | 86 |
| Median PFS | n.d. | n.d. |
| 2-y PFS | n.d. | 82.1% |
| Reference Clinical trial | 37 | 38 NCT01712490 |
| CD33 | Lintuzumab | Gemtuzumab |
| Cytotoxic payload | Calicheamicin | |
| Indication/status | R/R AML (phase 3 study, failed) | R/R AML (FDA approved) |
| ORR, % | 36 | 38.8 |
| Median PFS | Median survival 171.5 d | 1 y RFS 18.5% |
| Median OS | n.d. | 1 y OS 26% |
| Reference Clinical trial | 39 NCT00006045 | 40 |
| CD79b | No clinical data available | Polatuzumab |
| Cytotoxic payload | Monomethylauristatin E (MMAE) | |
| Indication/status | R/R DLBCL (FDA approved) | |
| Median PFS | 9.5 mo | |
| 1-y PFS | n.d. | |
| CR, % | 40 | |
| Reference Clinical trial | 24 NCT02257567 |
n.d., not determined; OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival; R/R ALL, relapsed/refractory acute lymphoblastic leukemia; R/R AML, relapsed/refractory acute myeloid leukemia; R/R B-NHL, relapsed/refractory B-cell non-Hodgkin lymphoma.